Ana Blázquez

Grupo de investigación

Psiquiatría y psicología infantil y adolescente Accredited researcher (R3A)

abhinojo@clinic.cat 0000-0001-6797-6890

Publicaciones destacadas

Association of regulatory TPH2 polymorphisms with higher reduction in depressive symptoms in children and adolescents treated with fluoxetine

Autores:
Gassó P; Rodríguez N; Boloc D; Blázquez A; Torres T;

(...)

Plana M; Lafuente A; Mas S; Arnaiz J; Lázaro L.

Referencia: Progress In Neuro-Psychopharmacology & Biological Psychiatry 2017.
Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine

Autores:
Gassó P; Rodríguez N; Blázquez A; Monteagudo A; Boloc D;

Plana MT; Lafuente A; Lázaro L; Arnaiz JA; Mas S .

Referencia: Progress In Neuro-Psychopharmacology & Biological Psychiatry 2017.
EPIGENETIC AND GENETIC VARIANTS IN THE HTR1B GENE AND CLINICAL IMPROVEMENT IN CHILDREN AND ADOLESCENTS TREATED WITH FLUOXETINE

Autores:
Gasso, P.; Rodriguez, N.; Blazquez, A.; Monteagudo, A.; Boloc, D.;

Plana, M. T.; Lafuente, A.; Lazaro, L.; Arnaiz, J. A.; Mas, S.;.

Referencia: Basic & Clinical Pharmacology & Toxicology 2017.
ASSOCIATION OF REGULATORY TPH2 POLYMORPHISMS WITH HIGHER REDUCTION IN DEPRESSIVE SYMPTOMS IN CHILDREN AND ADOLESCENTS TREATED WITH FLUOXETINE

Autores:
Torres, T.; Gasso, P.; Rodriguez, N.; Boloc, D.; Blazquez, A.;

Gortat, A.; Plana, M. T.; Lafuente, A.; Mas, S.; Lazaro, L.;.

Referencia: Basic & Clinical Pharmacology & Toxicology 2017.
Pharmacogenetic study focused on fluoxetine pharmacodynamics in children and adolescent patients: impact of the serotonin pathway

Autores:
Mas S; Blázquez A; Rodríguez N; Boloc D; Lafuente A;

Arnaiz JA; Lázaro L; Gassó P .

Referencia: Pharmacogenetics And Genomics 2016.
One-Year Follow-up of Children and Adolescents with Major Depressive Disorder: Relationship between Clinical Variables and Abcb1 Gene Polymorphisms

Autores:
Blazquez, A.; Gasso, P.; Mas, S.; Plana, M. T.; Lafuente, A.;

Lazaro, L.;.

Referencia: Pharmacopsychiatry 2016.
Differences in Psychopathology Between Immigrant and Native Adolescents Admitted to a Psychiatric Inpatient Unit

Autores:
Blazquez, Ana; Castro-Fornieles, Josefina; Baeza, Inmaculada; Morer, Astrid; Martinez, Esteban;

Lazaro, Luisa.

Referencia: Journal Of Immigrant And Minority Health 2015.
Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients

Autores:
Gasso, P; Rodriguez, N; Mas, S; Pagerols, M; Blazquez, A;

Plana, M T; Torra, M; Lazaro, L; Lafuente, A.

Referencia: Pharmacogenomics Journal 2014.
Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder

Autores:
Blazquez, Ana; Mas, Sergi; Plana, Maria Teresa; Gasso, Patricia; Mendez, Iria;

Torra, Merce; Arnaiz, Joan Albert; Lafuente, Amalia; Lazaro, Luisa.

Referencia: Journal Of Clinical Psychopharmacology 2014.
Fluoxetine pharmacogenetics in child and adult populations

Autores:
Blazquez, Ana; Mas, Sergi; Teresa Plana, MA; Lafuente, Amalia; Lazaro, Luisa;

Referencia: European Child & Adolescent Psychiatry 2012.

Proyectos destacados

5TA-B-001, lnternational, multicentric, observational study to characterize the clinical subpopulations of patients with ASD.

Duración: 01/01/2023
pM21/00051, Estudio integrat devariación genética y motecutar de una cohorte españota de autismo y diseño de atgoritmos de diagnóstico genético y de biotipos terapéuticos.Cohorte ESTEA

Financiador: Instituto de Salud Carlos III

Duración: 02/02/2022
AP171442019, Caracterización gen REPS2 como nuevo gen candidato para los trastornos del neurodesarrollo.

Financiador: Fundació Mutua Madrileña (Programa financiador competitivo)

Duración: 10/09/2019
15300, European Autism lnterventions - a Multicentre Study for Developing New Medications (EU-AIMS-2-Trials)

Duración: 12/10/2018

Ana Blázquez

Grupo de investigación

Publicaciones destacadas

EPIGENETIC AND GENETIC VARIANTS IN THE HTR1B GENE AND CLINICAL IMPROVEMENT IN CHILDREN AND ADOLESCENTS TREATED WITH FLUOXETINE

ASSOCIATION OF REGULATORY TPH2 POLYMORPHISMS WITH HIGHER REDUCTION IN DEPRESSIVE SYMPTOMS IN CHILDREN AND ADOLESCENTS TREATED WITH FLUOXETINE

Proyectos destacados

5TA-B-001, lnternational, multicentric, observational study to characterize the clinical subpopulations of patients with ASD.

pM21/00051, Estudio integrat devariación genética y motecutar de una cohorte españota de autismo y diseño de atgoritmos de diagnóstico genético y de biotipos terapéuticos.Cohorte ESTEA

AP171442019, Caracterización gen REPS2 como nuevo gen candidato para los trastornos del neurodesarrollo.

15300, European Autism lnterventions - a Multicentre Study for Developing New Medications (EU-AIMS-2-Trials)

Suscríbete a la Newsletter del Clínic